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Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild-to-moderate asthma. The SKY study
To the Editor, Histamine and cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators involved in both seasonal allergic rhinoconjunctivitis (SARC) and asthma. 1, 2 A combination therapy against both these agents may provide additive benefit, as demonstrated both in vitro 3 and in vivo. [4] [5] [6] We compared the efficacy and safety of concomitant therapy with bilastine, a second-generation H1 anti-histamine 7 and montelukast vs each agent alone in patient with SARC and asthma. We hypothesized that bilastine plus montelukast is superior to bilastine monotherapy in reducing SARC symptoms after 4 weeks and in improving asthma quality of life over a longer time period.
Adult patients with SARC and mild-to-moderate asthma partially controlled 8 by beclomethasone dipropionate or equivalent ≤500 μg/d (alone or in combination with long-term β 2 -adrenergic bronchodilators) were enrolled. Patients had a postbronchodilator FEV 1 > 70% of the predicted, a skin prick test positive to at least one seasonal allergen tested at enrolment or previously reported, and a nasal/ocular Total Symptom Score (TSS) ≥3. 9 Exclusion criteria are reported in the online supplementary. The study (EUDRA-CT number:2015-004806-40) was conducted in 50 centres across 6 European countries during the relevant regional pollen season for grasses, trees and weeds, with a double-blind, double-dummy, randomized, active-controlled and parallel-group design (Figure 1 ).
It consisted in a 1-week screening period followed by 12 weeks of treatment. During the study, patients quantified SARC symptoms by TSS, Daytime Nasal Symptom Score (DNSS) and Daytime non-Nasal Symptom Score (DNNS); use of rescue medications and occurrence of adverse events were noted. During screening, patients' medical history, vital signs, spirometry results and asthma quality of life questionnaire (AQLQ) scores were obtained. AQLQ was re-assessed after 4 and 12 weeks of treatment; ECG variables, blood and urine samples were re-obtained at the end of treatments for safety purposes.
Enrolled patients were randomly treated once daily with bilastine 20 mg plus montelukast 10 mg, or bilastine 20 mg plus placebo or montelukast 10 mg plus placebo ( Figure 1 ). Naphazoline nasal spray eye drops and salbutamol inhaler were rescue medications for SARC and acute asthma symptoms. Patients' compliance with treatments was calculated. The primary endpoint was changes in baseline TSS values following 4 weeks of treatment. 10 (Table S1 ).
All treatments significantly (P < .001) reduced baseline TSS values over 4 weeks ( Figure 2 ). Overall, the mean ± SD TSS reduction was −3.2 ± 3.7, with no significant differences among treatments. Mean TSS value observed 1 and 2 weeks after bilastine was significantly (P < .05) lower than after montelukast. (Figure 2 ). Mean TSS values decreased similarly with all treatments after 3 weeks ( Figure 2 ). However, bilastine reduced baseline TSS more than montelukast after 1 and 2 weeks of treatment (P always <.05). Similar findings were observed for DNSS and DNNSS (data not shown). Mean AQLQ increased similarly with all treatments after 4 and 12 weeks. The use of rescue medications for SARC and/or asthma did not differ among treatments, as was patients' compliance with treatments (98.3% overall). Drug-related incidence of adverse events was similar among the treatment groups (4.3% overall). No clinically significant changes in any laboratory tests, ECGs or vital signs were noted.
We compared for the first time the efficacy and safety of con- Bilastine alone improved SARC symptoms more than montelukast in the first 2 weeks of treatment. This finding is consisted with a more rapid effect of bilastine than montelukast, which may be of relevance for patients who need intermittent treatment to alleviate SARC symptoms. The absolute extent of the effect of these treatments on symptomatology or the use of rescue medication when treating SARC and concomitant asthma are impossible to gauge from this study because a group of patients treated entirely with placebo was not included.
Moreover, since changes in lung function were not monitored, it is difficult to gauge how far this improvement reflected possible effects of study treatments on bronchoconstriction and/or lower airways inflammation or how far they reflected a true placebo effect. Previous reports suggest that an improvement in SARC can also improve asthma control. 12 Thus, due to its beneficial effects on SARC symptoms, our results suggest that bilastine, when added to inhaled corticosteroids alone or in combination with long-term β 2 -adrenergic bronchodilators, could improve disease control in mild-to-moderate asthma patients.
In conclusion, treatment with bilastine plus montelukast over 4 weeks does not consistently produce further improvements in SARC symptoms and AQLQ beyond those provided by either agent alone. Thus, there is no benefit of using bilastine plus montelukast to provide relief of SARC symptoms in partially controlled, mild-tomoderate asthma patients.
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CO N FLI C T S O F I NTE R E S T
The SKY study was sponsored by Menarini International Operations Luxemburg SA (MIOL). Table S1 ), and only patients with mono-sensitization to vespid venom were included in the study. During the up-dosing phase, patients were treated with oral non-sedative antihistamines (histamine (H1) receptor blockers) one hour before injection. The purified depot preparation Alutard SQ ® vespid venom (ALK-Abelló) was administered with an initial dose of 1 μg followed by 5, 10, 20, 40, 60, 80, and 100 μg corresponding to 1.000, 5.000, 10.000, 20.000, 40.000, 60.000, 80.000, and 100.000 SQ at 1week intervals by single injections (injection interval: 7 to a maximum of 14 days). The maintenance phase required single injections every 4-6 weeks with 100 μg. To demonstrate that immunotherapy is effective immediately after up-dosing, sting challenges with live vespids (Vespula germanica or Vespula vulgaris) were performed, whenever possible, one week after reaching the maintenance dose.
We registered one withdrawal from the study according to the patients' wish, the other 75 completed up-dosing without dose reductions. Only 3 (3.9%, one-sided exact 97.5% confidence interval [CI] 0.0-11.1) patients showed objective symptoms which were mild and limited to the skin, and 5 (6.6%, one-sided exact
